Lung Cancer Trials Ask AI to find trials
CompletedPhase 1NCT01059552
Official study title

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Study summary

The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedvorinostat

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 27, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?3 U.S. locations

Locations may change over time.

Who runs it?Fox Chase Cancer Center

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Fox Chase Cancer Center
Interventions being studied
Drug: vorinostat
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→Locally advanced→
Treatment approach
Chemotherapy→Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • biopsy proven non-squamous NSCLC with unresectable stage IIIA or dry IIIB disease.
  • FEV1 \>/= 1 liter
  • ECOG PS 0 or 1
  • Able to swallow and absorb enterally
  • Measurable disease per RECIST 1.1
  • Adequate organ and marrow function including calculated creatinine clearance \>/= 60 mL/min hepatic enzymes and alk phos \</= 2.5 X ULN.
Reasons someone may not be able to joinExclusion criteria
  • Chemotherapy or radiotherapy \</= 4 weeks prior to registration (6 weeks for nitrosureas)
  • Active bleeding
  • Known brain mets
  • Prior thoracic radiotherapy that would lead to overlap with current radiation field.
  • More than 10% weight loss in 6 months.
  • Pancoast tumors, supraclavicular or contralateral hilar lymph node involvement
  • Known HIV positive
  • Prior treatment with an HDAC inhibitor

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Moffitt Cancer CenterTampa, Florida
  • Fox Chase Cancer CenterPhiladelphia, Pennsylvania
  • Medical University of South CarolinaCharleston, South Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 27, 2019. Always confirm current availability with the study team.

View original record ↗